Drug approval-patent link system that delays market entry of generic drugs doesn’t seem to imperil pharmaceutical industry

The report 'status and performance of 2 years implementation of Korea-US FTA’  published in recent by Korea Institute for International Economic Policy states that drug approval-patent link system plays a role that delays market entry of generic drugs but implication would be restrictive.

Since objects for this system are only eligible in case of insisting that they did not infringe existing p...